Clenbuterol for Thermogenic Fat Loss & Bronchodilation — Weight & Metabolism

Overview

Clenbuterol hydrochloride is a selective beta-2 adrenergic receptor agonist originally developed as a bronchodilator for the treatment of asthma and chronic obstructive pulmonary disease. It is FDA-approved as a veterinary drug (Ventipulmin) for the treatment of airway obstruction in horses, but is NOT approved for human use in the United States. In some European, Asian, and Latin American countries, clenbuterol is approved for human use as a bronchodilator (brand names include Spiropent, Clenasma). Clenbuterol has been widely abused in bodybuilding and athletics communities for its thermogenic and anti-catabolic properties. The compound stimulates beta-2 adrenergic receptors, increasing intracellular cAMP levels which activate protein kinase A (PKA) and hormone-sensitive lipase (HSL), promoting lipolysis and fatty acid oxidation. Additionally, clenbuterol increases basal metabolic rate by approximately 10-15% through stimulation of uncoupling protein expression and mitochondrial thermogenesis. Animal studies demonstrate significant anti-catabolic effects through inhibition of the ubiquitin-proteasome pathway, though human evidence for muscle-sparing properties is limited. The elimination half-life is approximately 36 hours, contributing to prolonged sympathomimetic effects. A major pharmacological limitation is beta-2 receptor downregulation, which occurs within 2-3 weeks of continuous use, reducing thermogenic efficacy. This is commonly addressed through cycling protocols (2 weeks on/2 weeks off) or co-administration of ketotifen, an antihistamine that upregulates beta-2 receptors. Cardiac toxicity is the primary safety concern, including tachycardia, cardiac hypertrophy (demonstrated in animal models), arrhythmias, and myocardial ischemia. Multiple cases of clenbuterol-associated myocardial infarction have been reported in the literature (PMID: 21960318). Clenbuterol is prohibited by WADA and the International Olympic Committee.

Indications

• Veterinary bronchodilator for equine airway obstruction (FDA-approved for horses)
• Human bronchodilator for asthma/COPD in select countries (not US)
• Widely abused for thermogenic fat loss enhancement
• Investigated anti-catabolic agent for muscle wasting conditions (preclinical)
• Misused for body composition improvement in bodybuilding
• Illegal use in livestock for lean meat production in some countries

Mechanism of Action

Clenbuterol HCl is rapidly absorbed orally with high bioavailability. Long half-life (~36hrs) provides sustained beta-2 stimulation. Peak plasma concentration within 2-3 hours of administration

Dosing

Evidence Grade

GRADE C

Safety & Contraindications

• NOT approved for human use in the United States
• Cardiac hypertrophy demonstrated in animal models — may be irreversible
• Tachycardia and palpitations — dose-dependent cardiovascular stimulation
• Myocardial infarction cases reported in literature (PMID: 21960318)
• Tremors (especially hands) — very common, usually dose-dependent
• Muscle cramps due to taurine depletion — supplementation recommended
• Insomnia and anxiety from sympathomimetic stimulation
• Hypokalemia risk — potassium monitoring recommended
• Beta-2 receptor downregulation within 2-3 weeks — requires cycling
• WADA and IOC prohibited substance
• Contaminated meat products have caused inadvertent positive drug tests
• Overdose can cause life-threatening cardiac arrhythmias